SANTA ROSA, Calif.--July 15, 2003 -- Endomatrix Inc., developer of a patented Endothelial Dysfunction Therapy (EDT) focused on treating the root cause of cardiovascular disease, announced today that it has signed dose-form development and manufacturing agreements with Capsugel(R), a division of Warner Lambert, a Pfizer Company. The agreements call for Capsugel to develop and subsequently manufacture the first Endomatrix product, Provasca, in Capsugel's proprietary Licap(R) oral dosage form.
Provasca, from Endomatrix, is a proprietary and patented nutraceutical product designed to address endothelial dysfunction, which affects the walls of arteries. Endothelial dysfunction can lead to inflammation of the arteries and supports cholesterol accumulation, both of which are known-causes of cardiovascular disease.
"Developing and manufacturing Provasca in a proprietary, state-of-the-art oral dosage form, the Licap from Capsugel, is an integral part of our strategy, and will allow us to get our breakthrough Endothelial Dysfunction Therapy (EDT) into the hands of consumers by the end of this year," stated Bruce Bouche', DC, Endomatrix's Vice President, Global Nutraceuticals. "Having Provasca manufactured by Capsugel, the world leader in capsule development and manufacturing, not only provides our customers with the highest quality product, but also provides additional patent protection for Provasca."
Provasca is the first in a line of products planned by Endomatrix, all of which will be based on the company's patented EDT. Endomatrix is led by a veteran team of medical industry executives with a track record of success at such companies as Medtronic AVE (NYSE:MDT), Guidant Corporation (NYSE:GDT) and Baxter Healthcare Corporation (NYSE:BAX).
Endomatrix Inc., has developed a breakthrough platform for the treatment and prevention of endothelial-based disease states, focusing on the root cause of disease rather than the symptoms. Founded in 2000, and based in Santa Rosa, Calif., Endomatrix is focused on delivering its platform to a global audience through both nutraceutical and pharmaceutical products.